Cytek Biosciences, Inc.(CTKB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,769 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CTKB Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Cytek Biosciences, Inc. (CTKB), a Technology sector company. 13F Pro's AI-powered ranking engine scores CTKB at 21.4/100 on a 32-signal composite quality model, placing it at rank #2,769 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (11.0) and profitability (11.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Cytek Biosciences, Inc. reports quarterly revenue of $48.1M, net income of $-12.2M, an operating margin of -23.7%. Top institutional holders of CTKB by reported 13-F value include BlackRock, MILLENNIUM MANAGEMENT, Boston Partners, based on the most recent SEC filings. CTKB trades on the Nasdaq exchange and files with the SEC under CIK 1831915. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTKB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cytek Biosciences, Inc. directly from SEC EDGAR. Cytek Biosciences, Inc.'s 13F Pro composite quality score has ranged between 21 and 46 since 2022, currently 21.4 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$48.1M
Net Income
Q2 2026
$-12.2M
Free Cash Flow
Q2 2026
$-849.0K
Operating Margin
Q2 2026
-23.7%
ROIC
Q2 2026
-14.2%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+0.5% YoYNet Income
-1005.3% YoYOperating Income
-96.8% YoYEPS (Diluted)
Total Assets
-7.6% YoYOp. Cash Flow
-118.5% YoYFree Cash Flow
-140.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $201.5M +0.5% | $200.5M +3.9% | $193.0M +6414.2% | $3.0M +35.9% | $2.2M +207.2% | $710.0K |
| Net Income | $-66.5M -1005.3% | $-6.0M +50.4% | $-12.1M -589.0% | $2.5M -17.9% | $3.0M -84.4% | $19.4M |
| Operating Income | $-40.4M -96.8% | $-20.5M +26.3% | $-27.8M -1443.5% | $-1.8M -119.7% | $9.2M -33.0% | $13.7M |
| EPS (Diluted) | — | — | $-0.09 -550.0% | $0.02 | $0.00 -100.0% | $0.07 |
| Total Assets | $461.5M -7.6% | $499.5M +1.0% | $494.5M -4.8% | $519.5M +12.1% | $463.3M +110.6% | $220.0M |
| Operating Cash Flow | $-4.7M -118.5% | $25.4M +380.6% | $5.3M +143.2% | $-12.2M -364.2% | $4.6M -69.5% | $15.2M |
| Free Cash Flow | $-8.8M -140.1% | $21.9M +3352.4% | $633.0K +102.9% | $-22.0M -8362.8% | $266.0K -98.0% | $13.6M |
Get alerted when CTKB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Cytek Biosciences, Inc. including:
Top Institutional Holders of CTKB
BlackRock, Inc.
$42.4M9,578,643 shMILLENNIUM MANAGEMENT LLC
$41.4M9,338,010 shBoston Partners
$33.9M7,660,943 shHillhouse Capital Advisors, Ltd.
$29.5M6,657,030 shTopline Capital Management, LLC
$27.8M6,283,450 shVANGUARD CAPITAL MANAGEMENT LLC
$21.9M4,939,597 shGEODE CAPITAL MANAGEMENT, LLC
$13.6M3,059,573 shDIMENSIONAL FUND ADVISORS LP
$11.6M2,616,257 shSTATE STREET CORP
$11.4M2,566,121 shGOLDMAN SACHS GROUP INC
$9.6M2,167,515 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $42.4M | 9,578,643 |
| MILLENNIUM MANAGEMENT LLC | $41.4M | 9,338,010 |
| Boston Partners | $33.9M | 7,660,943 |
| Hillhouse Capital Advisors, Ltd. | $29.5M | 6,657,030 |
| Topline Capital Management, LLC | $27.8M | 6,283,450 |
| VANGUARD CAPITAL MANAGEMENT LLC | $21.9M | 4,939,597 |
| GEODE CAPITAL MANAGEMENT, LLC | $13.6M | 3,059,573 |
| DIMENSIONAL FUND ADVISORS LP | $11.6M | 2,616,257 |
| STATE STREET CORP | $11.4M | 2,566,121 |
| GOLDMAN SACHS GROUP INC | $9.6M | 2,167,515 |
Companies Similar to CTKB
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
CS Disco, Inc.
REZOLVE AI PLC
INSEEGO CORP.
SOUNDTHINKING, INC.
NETGEAR, INC.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Cognyte Software Ltd.
Quanterix Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Technology Companies
View all Technology →Put CTKB on your watchlist
Track score changes the day Cytek Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CTKB a good stock to buy?
13F Pro's AI-powered analysis of Cytek Biosciences, Inc. (CTKB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CTKB are available on the CTKB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CTKB is classified as a small company.
Which hedge funds own CTKB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CTKB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cytek Biosciences, Inc.'s investment landscape.